Sandbox Reserved 1657: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 37: | Line 37: | ||
'''Notch3 NRR :''' receives a signal and transmits it in the cell to initiate a change in cell activity.It can also used in the neuron fate commitment, artery morphogenesis or the regulation of NOTCH signaling pathway | '''Notch3 NRR :''' receives a signal and transmits it in the cell to initiate a change in cell activity.It can also used in the neuron fate commitment, artery morphogenesis or the regulation of NOTCH signaling pathway | ||
'''MOR 20358 :''' an Anti-Human Notch 3 recombinant antibody designed for therapeutic purpose in the curing of the T-Cell Acute lymphoblastic leukemia disease. | '''MOR 20358 :''' an Anti-Human Notch 3 [https://en.wikipedia.org/wiki/Recombinant_antibodies recombinant antibody] designed for therapeutic purpose in the curing of the T-Cell Acute lymphoblastic leukemia disease. | ||
The study<ref name="oncogene">Bernasconi-Elias, P., Hu, T., Jenkins, D. et al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 35, 6077–6086 (2016). https://doi.org/10.1038/onc.2016.133</ref> for which it was designed has provided evidence that MOR 20358 binds to half of the LRN-C linker and parts of the HD-C and the LNR-B/C domains, which would therefore lock the Notch 3 NRR in an auto-inhibitory conformation, ending up inhibiting the Notch signalling. This property may constitute a treatment in cases of Notch3 over-activation related cancers. | The study<ref name="oncogene">Bernasconi-Elias, P., Hu, T., Jenkins, D. et al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 35, 6077–6086 (2016). https://doi.org/10.1038/onc.2016.133</ref> for which it was designed has provided evidence that MOR 20358 binds to half of the LRN-C linker and parts of the HD-C and the LNR-B/C domains, which would therefore lock the Notch 3 NRR in an auto-inhibitory conformation, ending up inhibiting the Notch signalling. This property may constitute a treatment in cases of Notch3 over-activation related cancers. | ||
